Treatment with ixekizumab, an IL-17 blocker used to treat psoriasis, preceded new psoriasiform eruptions [18] in one patient, photosensitive cutaneous eruptions [19] in another, and lentiginous eruption [20] in a third patient. This evidence concerns the gene IL17A and psoriasis.